2015
Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals
May MT, Justice AC, Birnie K, Ingle SM, Smit C, Smith C, Neau D, Guiguet M, Schwarze-Zander C, Moreno S, Guest JL, Monforte A, Tural C, Gill MJ, Bregenzer A, Kirk O, Saag M, Sterling TR, Crane HM, Sterne JA. Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2015, 69: 348-354. PMID: 25848927, PMCID: PMC4506784, DOI: 10.1097/qai.0000000000000603.Peer-Reviewed Original ResearchConceptsInjection drug useDrug useLiver-related mortalityHepatitis C infectionEffect of HCVMortality hazard ratioNorth American cohortHCV coinfectionHCV statusAntiretroviral therapyC infectionHepatitis CHazard ratioSurvival differencesRisk factorsExcess mortalityPoor survivalRisk groupsHCVAmerican cohortHIVNew treatmentsMortalitySubstantial proportionComplete data
2009
Measuring Persistence to Oral Hypoglycemic Agents in Type 2 Diabetic Veterans
Kim N, Agostini J, Justice A. Measuring Persistence to Oral Hypoglycemic Agents in Type 2 Diabetic Veterans. Journal Of Pharmacy Technology 2009, 25: 223-229. PMID: 21779543, PMCID: PMC3139220, DOI: 10.1177/875512250902500402.Peer-Reviewed Original ResearchOral hypoglycemic agentsHypoglycemic agentsDiabetic veteransTotal daysStudy entryMedian persistenceKappa agreement statisticsContinuous refillMultiple comorbiditiesMost patientsMedian ageDiabetes controlMedication adherenceInclusion criteriaEligible veteransPoor persistenceSubstantial proportionClinical applicationVeteransPatientsFirst yearAgreement statisticsDaysPrescriptionContinuous fill